Efavirenz is used in combination with other HIV medicines to help control HIV infection by reducing the amount of HIV in a person's body so that the immune system can work better. This helps reduce your risk of HIV complications (such as new infections, cancer) and improves your quality of life.

Efavirenz was approved for use in 1998 in the US. Efavirenz belongs to the group of non-nucleotide reverse transcriptase inhibitors. After the HIV virus enters the host cell, the HIV RNA strand is released, and the single strand RNA is reverse transcribed to form DNA by reverse transcriptase. Reverse transcriptase inhibitors, which prevent viral RNA from being copied into DNA, prevent HIV from replicating.

Efavirenz 600 contains the main active ingredient Efavirenz with a content of 600mg, manufactured by Ampharco USA Pharmaceutical Joint Stock Company. Efavirenz is an antiviral drug that prevents HIV, a virus that causes human immunodeficiency, from multiplying in the body.